Background: This evidence-based guideline is an update of the 2005 American Academy of Neurology practice parameter on the treatment of essential tremor (ET).
Essential tremor (ET) is the most common tremor disorder and often affects activities of daily living, including writing and eating. 1 The head and voice are commonly affected. Diagnostic criteria for ET may be found in the Consensus Statement of the Movement Disorder Society on Tremor. 2 Propranolol and primidone are the medications used most frequently and successfully to treat ET, and propranolol is the only medication approved by the US Food and Drug Administration to treat ET. Unfortunately, 30% to 50% of patients will not respond to either primidone or propranolol. 3 This evidence-based guideline is an update of the American Academy of Neurology (AAN) 2005 practice parameter regarding treatment of ET 4 and includes relevant research published since the 2005 publication.
DESCRIPTION OF THE ANALYTIC PROCESS
The AAN invited neurologists with expertise in ET to perform the review. Computer-assisted literature searches were conducted for relevant Englishlanguage articles pertinent to the treatment of ET. The MEDLINE, EMBASE, Science Citation Index, and CINAHL databases were searched from the years 2004 to 2010. Appendix e-1 on the Neurology ® Web site at www.neurology.org lists the key words and phrases used in the search.
The search identified 589 articles pertaining to the treatment of ET, the titles and abstracts of which were each reviewed by at least 2 committee members. Articles were accepted for further review if they consisted of controlled trials, observational studies, cohort studies, open-label studies, or case series. Of the 589 articles, 252 were reviewed in their entirety. Panel members who were authors of reviewed studies did not grade their own research.
ANALYSIS OF EVIDENCE Pharmacologic agents without evidence to change the conclusions or recom-
mendations. There were no additional trials published since the previous guideline and rated better than Class IV that examined the efficacy and safety of propranolol, primidone, alprazolam, atenolol, gabapentin (monotherapy), sotalol, propranolol for head tremor, clonazepam, nadolol, nimodipine, botulinum toxin, clozapine, acetazolamide, isoniazid, pindolol, trazodone, methazolamide, mirtazapine, nifedipine, verapamil, sodium oxybate (in ethanolsensitive ET), oxcarbazepine, tiagabine, amantadine, clonidine, gabapentin (adjunct therapy), glutethimide, l-tryptophan/pyridoxine, metoprolol, nicardipine, phenobarbital, quetiapine, and theophylline. 4 Several new Class II studies addressed the efficacy of topiramate for ET. 5, 6 The results of these studies confirmed those of previous studies showing efficacy of topiramate for ET and do not lead to a change in the previous guideline's recommendation. Olanzapine. Olanzapine, an atypical antipsychotic, was compared with propranolol in one Class III study of limb tremor. 7 Thirty-eight patients were randomized to receive olanzapine (20 mg/day) or propranolol (120 mg/day) in a crossover study and were evaluated at baseline and after 1 month. Propranolol and olanzapine significantly reduced scores on all evaluation measures, although a placebo effect cannot be ruled out. The evidence is insufficient to support or refute the efficacy of olanzapine for ET (single Class III study).
Surgical interventions without evidence to change the conclusions or recommendations.
There were no additional trials rated better than Class IV that examined the efficacy and safety of thalamotomy for contralateral limb tremor, gamma knife thalamotomy, or deep brain stimulation (DBS) of the thalamus for the treatment of ET. Moreover, no additional trials rated greater than Class IV were available that assessed the relative efficacy of thalamotomy vs thalamic DBS, bilateral vs unilateral surgical procedures, or direct subthalamic vs zona incerta/prelemniscal stimulation. 4 Table e-2 summarizes the previous conclusions and recommendations pertaining to surgical interventions.
Clinical context. No high-quality, long-term studies exist regarding the efficacy and safety of these interventions for ET.
Pharmacologic agents with evidence supporting new conclusions or recommendations. Levetiracetam. One Class I study and 2 Class II studies investigated the efficacy of levetiracetam in ET. The randomized, crossover Class I study evaluated the acute effects of a single dose of levetiracetam on limb tremor and found some improvement in line drawing at 70 and 130 minutes ( p Ͻ 0.007), whereas other tests did not show improvement (handwriting at 70 and 130 minutes and spirals at 70 minutes). 8 Because the clinical relevance of the short-term outcome in this Class I study is unclear, the study was not considered further. Two Class II randomized, crossover studies showed no benefit of levetiracetam for ET. 9, 10 Conclusion. Levetiracetam probably does not reduce limb tremor in ET (2 Class II studies).
3,4-Diaminopyridine. One adequately powered Class I study failed to find any improvement in ET with 3,4-diaminopyridine. 11 Conclusion. 3,4-Diaminopyridine probably does not reduce limb tremor in ET (1 Class I study).
Flunarizine. Flunarizine is a selective calcium channel blocker. Two Class III studies using blinded video analysis found flunarizine to be ineffective in treating ET. 12, 13 Conclusion. Flunarizine possibly has no effect in reducing limb tremor in ET (2 Class III studies).
Pregabalin. The effect of pregabalin on tremor was evaluated in 2 Class II studies. One study was a randomized, parallel-group, double-blind, placebocontrolled trial of 22 patients with ET. 14 Pregabalin was initiated at 50 mg/day and escalated by 75 mg/ day every 4 days to a maximum dose of 600 mg/day. Significant reduction in tremor amplitude in the pregabalin group at a mean dose of 286 mg/day and improvement in action tremor limb scores on the Fahn-Tolosa-Marin (FTM) Tremor Rating Scale (TRS) were observed. A second Class II randomized, crossover study of pregabalin in 20 patients with ET found no improvement in any of the TRS measures and a significant worsening of Quality of Life in Essential Tremor Questionnaire scores. 15 Patients were treated with pregabalin (150 -600 mg/day) or placebo, titrated over 6 weeks. Reported adverse events in these studies included drowsiness and dizziness.
Conclusion. The evidence is insufficient to support or refute the efficacy of pregabalin for ET (conflicting Class II studies).
Zonisamide. The effect of zonisamide, an antiepileptic medication, in ET was investigated in 2 Class III and several open-label studies. 16 -18 One Class III doubleblind, placebo-controlled, randomized trial evaluated the efficacy and tolerability of zonisamide in treating ET in 20 patients at a mean dose of 160 Ϯ 50 mg/ day. 17 No significant improvements in the FTM total score or its subsections were observed at the study end-point, although tremor amplitude as assessed by accelerometry significantly improved in the zonisamide group at endpoint relative to baseline. Another evaluatorblinded Class III study found significant improvements in FTM rating scores in patients treated with zonisamide in both the blinded treatment phase and the open-label extension phase, with mean doses of zonisamide of 252 mg/day and 225 mg/day, respectively. 16 Conclusion. The evidence is insufficient to support or refute the efficacy of zonisamide for ET (conflicting Class III studies).
Clozapine. Clozapine, an antipsychotic medication that received a Level C recommendation in the 2005 practice parameter, has been downgraded to a Level U recommendation because of a trial that evaluated the acute effects of clozapine in a controlled setting, followed by a chronic open-label phase of the study in "responders" 19 (Level U for chronic use).
Conclusion. The evidence is insufficient to support or refute the efficacy of clozapine for chronic use in the treatment of ET. Clinicians may choose not to consider flunarizine for treatment of limb tremor in ET (Level C).
The evidence is insufficient to make recommendations regarding the use of pregabalin, zonisamide, or clozapine (Level U).
CLINICAL CONTEXT Flunarizine use may result in development of movement disorders, including akathisia, dyskinesia, dystonia, and parkinsonism.
As an atypical neuroleptic agent, olanzapine can induce parkinsonism. A review of 11 published studies of olanzapine use in patients with PD found reports of worsening parkinsonism in 64 of 145 patients (44%). 20 However, this side effect was not observed in the study of patients with ET.
ET is a common movement disorder, and Class I evidence supports the successful use of primidone and propranolol in ET treatment. However, not all patients improve on or tolerate these medications. A survey of 223 patients in a clinical database revealed that 70.9% had taken primidone or propranolol, and 56.3% had discontinued one or both medications. 21 Thus, these first-line medications for ET clearly fail to meet the needs of many patients.
RECOMMENDATIONS FOR FUTURE RESEARCH
Controlled clinical trials of additional medications are needed using standardized outcome measures of tremor, including disability scales and cost-benefit analyses.
The pursuit of better treatments for ET is hampered by our limited understanding of the pathophysiology of ET. Despite its high prevalence, few postmortem studies had historically been conducted. Recent postmortem evidence, however, indicates the presence of a heterogeneous set of degenerative changes in the brains of people with ET, indicating that ET is likely to be a syndrome or family of diseases rather than a single disease, which adds a layer of complexity to matters. Furthermore, the sequence of molecular events that underlie these degenerative changes has yet to be elucidated, and until such a time, it will be difficult to design specific targets for pharmacotherapeutic intervention.
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